CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Christopher Anzalone

Chairman, Chief Executive Officer & President, ARROWHEAD PHARMACEUTICAL INC

Search every verified Christopher Anzalone interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In an October 2026 interview on The BioCentury Show, Christopher Anzalone discussed Arrowhead Pharmaceuticals' progress in RNA interference (RNAi) therapies, noting the company's ability to deliver siRNA to seven cell types and new data on subcutaneous delivery to the brain. He described the company's history in the field, including its acquisition of RNAi businesses from Roche in 2011 and Novartis in 2014, and emphasized the importance of directed delivery for siRNA, contrasting it with the broad distribution of small molecules. Anzalone also commented on the competitive landscape, stating that while ASOs have a place, properly designed siRNA molecules generally offer advantages in durability, knockdown level, and safety for gene silencing. Anzalone addressed specific pipeline programs, including the Lp(a) therapy olpasiran partnered with Amgen, and discussed the growth outlook for plozasiran in severe hypertriglyceridemia. He referenced early data from Arrowhead's obesity programs, describing the results as compelling and well tolerated, with knockdown of target genes and effects on LDL and triglycerides. He noted that LDL is a well-validated biomarker and expressed interest in the program's future directions.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →